Exopharm appoints two key executives as it transitions into a global exosomes company
Health & Biotech
Health & Biotech
Link copied to
The key appointments announced today will help Exopharm to engage international players, and support its ambitious goal to become a global exosome medicines company.
Clinical stage biotech company, Exopharm (ASX:EX1), has appointed two new executives into its leadership team, as it looks to transition into a global company.
The company has appointed David Oxley as president – international, and Dr Johannes K Mühl as senior vice president – finance.
Oxley’s appointment will support Exopharm’s goal to reach a growing network of global and regional strategic partners and international capital markets.
He brings more than 20 years professional experience, including complex cross-border licensing expertise, product candidate development and approval, commercialisation, and capital markets.
Within the biotech sector, Oxley has had extensive experience including 10 years of leadership roles in regenerative medicine in China, Australia, and the US.
He has also previously served on the board of directors of a private, antibody-based bioscience company, along with a not-for-profit foundation focused on infectious diseases in Africa.
Oxley spent 18 years in executive leadership roles in the life sciences arena, including head of global sales, and head of global government relations.
He held those positions in medical devices companies, a leading US bank, as well as stints as a policy advocate before the US FDA and healthcare legislative work for a member of the US Congress.
Meanwhile, Mühl is based in Zurich, and has a vast network in the life-science industry as well as being a successful private investor in the biotech sector.
He will help build Exopharm’s profile in the investment community, and shape the company’s pipeline of products along with the associated strategy.
Mühl brings with him a wealth of skills, including analytical precision, deep understanding of finance and accounting across continents, deal making, and a thorough knowledge of the gene therapeutics and diagnostics market.
His previous roles include international head of Finance and Business Insights at Myriad Genetics ,where he co-led the organisation through a successful transformation with growth of top and bottom line.
He also has over 15 years of life-science industry finance experience with roles at Pfizer and Zimmer Biomet.
Exopharm has made major progress in its LEAP technology this year, which includes a research collaboration with Japan’s Showa Denko Materials (SDMC) signed in September.
Under the feasibility study agreement, SDMC will evaluate Exopharm’s LEAP (Ligand-based Exosome Affinity Purification) technology platform in its Yokohama regenerative medicine business unit.
Exopharm’s patent-protected LEAP technology provides access to large quantities of high-purity exosomes for research and clinical use, and has the potential to significantly advance developments in the field.
LEAP uses a chromatography-based purification process to reduce the bottleneck and provide access to large quantities of high-purity exosomes.
The company says it’s the only technology available globally that offers low-cost, high scalability for exosome medicine purification.
Exopharm is currently awaiting patent approvals in 11 global jurisdictions where its applications are currently pending.
Included in that list is the US, where the company has already received fast-track approval from the US Patent Office which improves its prospects for an early grant.
Exopharm has also secured $12 million in capital raising to accelerate the commercialisation of the LEAP platforms.
This article was developed in collaboration with Exopharm, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.